Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease

Heather Wakelee, Sarita Dubey, David R Gandara

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The standard of care for resected stage II-IIIA nonsmall cell lung cancer (NSCLC) now includes adjuvant chemotherapy based on the results of three phase III studies using cisplatin-based regimens-the International Adjuvant Lung Trial, the National Cancer Institute of Canada JBR.10 trial, and the Adjuvant Navelbine International Trialist Association trial. The role of adjuvant chemotherapy for stage I disease remains controversial. A recent meta-analysis (the Lung Adjuvant Cisplatin Evaluation) showed potential harm with the addition of adjuvant cisplatin for stage IA disease and no survival benefit for this modality in stage IB disease. Updated results from the Cancer and Leukemia Group B 9633 trial, the only trial to focus exclusively on stage IB patients, no longer show a statistically significant survival benefit from adjuvant chemotherapy in this population, except for the subgroup of patients with larger tumors. It may be that trials have been underpowered to detect a small benefit for patients with stage IB disease, or there may really not be benefit to adding adjuvant therapy for this stage of disease. Additional markers, such as tumor size or the presence or absence of certain tumor proteins like ERCC1, may help to determine which patients with resected stage I NSCLC may benefit from adjuvant chemotherapy. Strategies such as inhibition of angiogenesis pathways and the epidermal growth factor receptor are under exploration.

Original languageEnglish (US)
Pages (from-to)331-337
Number of pages7
JournalOncologist
Volume12
Issue number3
DOIs
StatePublished - 2007

Fingerprint

Non-Small Cell Lung Carcinoma
Adjuvant Chemotherapy
Cisplatin
Neoplasms
Therapeutics
Lung
Survival
National Cancer Institute (U.S.)
Standard of Care
Epidermal Growth Factor Receptor
Canada
Meta-Analysis
Leukemia
Population
Proteins

Keywords

  • Adjuvant chemotherapy
  • Cisplatin
  • Lung cancer
  • Stage I

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease. / Wakelee, Heather; Dubey, Sarita; Gandara, David R.

In: Oncologist, Vol. 12, No. 3, 2007, p. 331-337.

Research output: Contribution to journalArticle

Wakelee, Heather ; Dubey, Sarita ; Gandara, David R. / Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease. In: Oncologist. 2007 ; Vol. 12, No. 3. pp. 331-337.
@article{ae5a94509df14974b9344cf6d3a4ca8f,
title = "Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease",
abstract = "The standard of care for resected stage II-IIIA nonsmall cell lung cancer (NSCLC) now includes adjuvant chemotherapy based on the results of three phase III studies using cisplatin-based regimens-the International Adjuvant Lung Trial, the National Cancer Institute of Canada JBR.10 trial, and the Adjuvant Navelbine International Trialist Association trial. The role of adjuvant chemotherapy for stage I disease remains controversial. A recent meta-analysis (the Lung Adjuvant Cisplatin Evaluation) showed potential harm with the addition of adjuvant cisplatin for stage IA disease and no survival benefit for this modality in stage IB disease. Updated results from the Cancer and Leukemia Group B 9633 trial, the only trial to focus exclusively on stage IB patients, no longer show a statistically significant survival benefit from adjuvant chemotherapy in this population, except for the subgroup of patients with larger tumors. It may be that trials have been underpowered to detect a small benefit for patients with stage IB disease, or there may really not be benefit to adding adjuvant therapy for this stage of disease. Additional markers, such as tumor size or the presence or absence of certain tumor proteins like ERCC1, may help to determine which patients with resected stage I NSCLC may benefit from adjuvant chemotherapy. Strategies such as inhibition of angiogenesis pathways and the epidermal growth factor receptor are under exploration.",
keywords = "Adjuvant chemotherapy, Cisplatin, Lung cancer, Stage I",
author = "Heather Wakelee and Sarita Dubey and Gandara, {David R}",
year = "2007",
doi = "10.1634/theoncologist.12-3-331",
language = "English (US)",
volume = "12",
pages = "331--337",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - Optimal adjuvant therapy for non-small cell lung cancer - How to handle stage I disease

AU - Wakelee, Heather

AU - Dubey, Sarita

AU - Gandara, David R

PY - 2007

Y1 - 2007

N2 - The standard of care for resected stage II-IIIA nonsmall cell lung cancer (NSCLC) now includes adjuvant chemotherapy based on the results of three phase III studies using cisplatin-based regimens-the International Adjuvant Lung Trial, the National Cancer Institute of Canada JBR.10 trial, and the Adjuvant Navelbine International Trialist Association trial. The role of adjuvant chemotherapy for stage I disease remains controversial. A recent meta-analysis (the Lung Adjuvant Cisplatin Evaluation) showed potential harm with the addition of adjuvant cisplatin for stage IA disease and no survival benefit for this modality in stage IB disease. Updated results from the Cancer and Leukemia Group B 9633 trial, the only trial to focus exclusively on stage IB patients, no longer show a statistically significant survival benefit from adjuvant chemotherapy in this population, except for the subgroup of patients with larger tumors. It may be that trials have been underpowered to detect a small benefit for patients with stage IB disease, or there may really not be benefit to adding adjuvant therapy for this stage of disease. Additional markers, such as tumor size or the presence or absence of certain tumor proteins like ERCC1, may help to determine which patients with resected stage I NSCLC may benefit from adjuvant chemotherapy. Strategies such as inhibition of angiogenesis pathways and the epidermal growth factor receptor are under exploration.

AB - The standard of care for resected stage II-IIIA nonsmall cell lung cancer (NSCLC) now includes adjuvant chemotherapy based on the results of three phase III studies using cisplatin-based regimens-the International Adjuvant Lung Trial, the National Cancer Institute of Canada JBR.10 trial, and the Adjuvant Navelbine International Trialist Association trial. The role of adjuvant chemotherapy for stage I disease remains controversial. A recent meta-analysis (the Lung Adjuvant Cisplatin Evaluation) showed potential harm with the addition of adjuvant cisplatin for stage IA disease and no survival benefit for this modality in stage IB disease. Updated results from the Cancer and Leukemia Group B 9633 trial, the only trial to focus exclusively on stage IB patients, no longer show a statistically significant survival benefit from adjuvant chemotherapy in this population, except for the subgroup of patients with larger tumors. It may be that trials have been underpowered to detect a small benefit for patients with stage IB disease, or there may really not be benefit to adding adjuvant therapy for this stage of disease. Additional markers, such as tumor size or the presence or absence of certain tumor proteins like ERCC1, may help to determine which patients with resected stage I NSCLC may benefit from adjuvant chemotherapy. Strategies such as inhibition of angiogenesis pathways and the epidermal growth factor receptor are under exploration.

KW - Adjuvant chemotherapy

KW - Cisplatin

KW - Lung cancer

KW - Stage I

UR - http://www.scopus.com/inward/record.url?scp=34147158870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147158870&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.12-3-331

DO - 10.1634/theoncologist.12-3-331

M3 - Article

C2 - 17405898

AN - SCOPUS:34147158870

VL - 12

SP - 331

EP - 337

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 3

ER -